HEREDITARY CANCER RISK, DIAGNOSTICS, AND TREATMENT STRATEGIES PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://
heredirtarycancerrisktreatmentstrat.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. Incidental findings in hereditary cancer testing.

A. Incidental findings refer to results unrelated to the initial testing indication that may have health implications

B. The main result that confirms the disease

C. Results from other organs' imaging

D. Family history details

2. What types of samples can be used for MyRisk testing?

A. Blood

B. Saliva

C. Blood or saliva

D. Urine

3. What is the inheritance pattern of HBOC and Lynch syndrome, and what does this imply for first-degree relatives?

A. Autosomal recessive

B. X-linked

C. Autosomal dominant

D. Mitochondrial

4. Which tier in Precise Tumor indicates FDA-approved therapy in the same cancer?

A. Tier I

B. Tier II

C. Tier III

D. Tier IA

5. Which sequencing technology does Precise Tumor use to analyze genetic material?

A. Next-generation sequencing (NGS) of DNA and RNA

B. Sanger sequencing

C. Microarray analysis

D. Quantitative PCR

6. Which statement about sequencing strategies for MRD is correct?

A. Exome sequencing identifies more variants than whole genome sequencing

B. Whole genome sequencing and exome sequencing have identical sensitivity

C. Whole genome sequencing identifies significantly more tumor variants than exome sequencing

D. Targeted panel sequencing is broader than whole genome sequencing

7. Are MSI and TMB automatically included in every Precise Tumor report?

A. MSI only

B. TMB only

C. MSI and TMB automatically included

D. Neither MSI nor TMB are included

8. Which scenario would most clearly indicate the use of Precise Tumor testing?

A. An advanced cancer patient seeking targeted therapy options

B. An early-stage cancer patient seeking screening

C. A patient with benign tumor planning surgery

D. A patient with an infectious disease

9. Is RiskScore equally accurate across ancestries?

A. Not studied

B. It varies significantly

C. No

D. Yes

10. Copy number variants in germline testing refer to which type of genetic change?

A. Single base substitutions.

B. Epigenetic changes.

C. Deletions or duplications that can be detected by methods like MLPA or microarray.

D. Balanced translocations.

Answers

1. A
2. C
3. A
4. D
5. A
6. C
7. C
8. A
9. D
10. C

Explanations

1. Incidental findings in hereditary cancer testing.

A. Incidental findings refer to results unrelated to the initial testing indication that may have health implications

B. The main result that confirms the disease

C. Results from other organs' imaging

D. Family history details

Incidental findings in hereditary cancer testing refer to results unrelated to the initial testing indication that may have health implications. When broad genetic panels are used to assess cancer risk, you can uncover pathogenic variants in genes that weren't being looked for, which may alter medical management for the patient and raise implications for family members. Because these findings weren't the primary reason for testing, they require upfront discussion about whether such secondary results will be reported and thorough post-test counseling to interpret significance and outline appropriate surveillance or preventive steps. The other options describe the main diagnostic result, imaging data, or non-genetic history details, which do not capture the idea of unexpected genetic results that could affect health.

2. What types of samples can be used for MyRisk testing?

A. Blood

B. Saliva

C. Blood or saliva

D. Urine

The main concept here is that MyRisk testing accepts more than one specimen type because it analyzes germline DNA and has been validated to work with DNA from both sources. Blood provides high-quality, high-quantity genomic DNA that's routinely used for sequencing panels. Saliva offers a convenient, non-invasive collection method and, with proper stabilization, yields DNA suitable for the same kind of sequencing and analysis. Both options are considered valid because the lab has demonstrated that DNA from either source meets the necessary quality and quantity for the multi-gene hereditary cancer panel. Urine isn't used for this test because it doesn't reliably provide the germline DNA required for comprehensive panel analysis; it usually isn't validated for this purpose, and the DNA obtained is not consistently adequate for accurate sequencing.

3. What is the inheritance pattern of HBOC and Lynch syndrome, and what does this imply for first-degree relatives?

A. Autosomal recessive

B. X-linked

C. Autosomal dominant

D. Mitochondrial

HBOC and Lynch syndrome are inherited in an autosomal dominant fashion. This means a single mutated copy of the relevant gene is enough to increase cancer risk. Because of this pattern, each first-degree relative (parent, child, or full sibling) of an affected person has a 50% chance of carrying the pathogenic variant. This makes family-based testing important: if a relative carries the mutation, they can pursue targeted surveillance and risk-reducing options; if they do not carry it, their inherited risk from these mutations is not elevated.

4. Which tier in Precise Tumor indicates FDA-approved therapy in the same cancer?

A. Tier I

B. Tier II

C. Tier III

D. Tier IA

In this tiering system, the highest level of evidence and regulatory support for using a targeted therapy is when the drug is FDA-approved for the exact cancer being treated with that biomarker. This is what Tier IA represents—the therapy is on-label for that specific cancer, providing the strongest, most actionable evidence for use. It means there is regulatory approval and established safety and efficacy in that exact tumor context. Other tiers cover scenarios like approvals in different cancers with the same biomarker or evidence from studies that aren't as definitive; they are informative but not as directly applicable as an on-label, cancer-specific approval.

5. Which sequencing technology does Precise Tumor use to analyze genetic material?

A. Next-generation sequencing (NGS) of DNA and RNA

B. Sanger sequencing

C. Microarray analysis

D. Quantitative PCR

Next-generation sequencing of DNA and RNA is the approach that provides the most comprehensive view of a tumor's genetic material. By sequencing both the genome and the transcriptome, this method detects a wide range of alterations: DNA-level changes such as point mutations, insertions and deletions, copy number variations, and structural rearrangements, plus RNA-level information like gene expression differences and fusion transcripts. The combination of breadth and depth lets a single test profile actionable mutations, expression patterns, and potential fusions that guide targeted therapies and clinical decisions. Sanger sequencing, while highly accurate for small regions, is not practical for broad tumor profiling because it sequences only one fragment at a time, making it slow and limited in scope. Microarray analysis can assess expression levels or copy-number changes but does not provide base-by-base sequence data and cannot readily identify novel variants. Quantitative PCR is fast and sensitive but is restricted to predefined targets and cannot comprehensively survey the genome or transcriptome. So, using next-generation sequencing of DNA and RNA offers the most versatile and informative analysis for Precise Tumor's genetic material.

6. Which statement about sequencing strategies for MRD is correct?

A. Exome sequencing identifies more variants than whole genome sequencing

B. Whole genome sequencing and exome sequencing have identical sensitivity

C. Whole genome sequencing identifies significantly more tumor variants than exome sequencing

D. Targeted panel sequencing is broader than whole genome sequencing

Whole-genome sequencing surveys the entire genome, including noncoding regions, whereas exome sequencing targets only the coding portions. Because many tumor mutations lie outside exons—in introns, regulatory regions, and in structural variants—whole-genome sequencing reveals a larger pool of detectable tumor variants than exome sequencing. In the context of MRD, this broader scope means more variants can potentially be identified, though sensitivity for any single low-frequency event often depends on sequencing depth and error suppression, which targeted deep panels prioritize for ultra-high detection. So, when considering the total number of tumor variants detectable, whole-genome sequencing identifies significantly more than exome sequencing. Exome sequencing cannot outpace WGS in variant discovery, their sensitivity is not identical due to differences in breadth and depth, and targeted panels are narrower, not broader, than whole-genome sequencing.

7. Are MSI and TMB automatically included in every Precise Tumor report?

A. MSI only

B. TMB only

C. MSI and TMB automatically included

D. Neither MSI nor TMB are included

In tumor profiling, MSI and TMB are key biomarkers used to guide immunotherapy decisions. MSI reflects mismatch repair deficiency, which can predict benefit from checkpoint inhibitors, while TMB measures the overall number of somatic mutations and can correlate with immunotherapy response in several cancers. Because these biomarkers provide important, actionable information for treatment options, many platforms design their reports to include both automatically. In the Precise Tumor report, these metrics are computed and presented as part of the standard output, so clinicians receive them without needing to request them separately. This automatic inclusion ensures you have essential data on immunotherapy suitability right away.

8. Which scenario would most clearly indicate the use of Precise Tumor testing?

A. An advanced cancer patient seeking targeted therapy options

B. An early-stage cancer patient seeking screening

C. A patient with benign tumor planning surgery

D. A patient with an infectious disease

Precise Tumor testing is used to identify genetic changes in a tumor that can be targeted with specific therapies, guiding personalized treatment. This approach is most clearly indicated when a patient has advanced cancer and needs targeted therapy options, because finding actionable mutations or gene alterations can directly inform which targeted drugs might work. In early-stage cancer, screening decisions rely more on detection and local treatment plans rather than profiling the tumor's mutations for drug choices. For a benign tumor, genetic testing isn't typically used to plan surgery since there aren't malignant drivers to target. An infectious disease scenario involves pathogens, not tumor cells, so tumor genetic testing wouldn't apply.

9. Is RiskScore equally accurate across ancestries?

A. Not studied

B. It varies significantly

C. No

D. Yes

Understanding cross-ancestry performance of a risk score hinges on how it's developed and validated. If a risk score is built using diverse ancestry data and then calibrated for each ancestry group, its discrimination and calibration can end up similar across populations. In that ideal setup, the score is designed to behave consistently regardless of ancestral background, so saying it's equally accurate across groups is reasonable. The key is deliberate inclusion of multiple ancestries during development, ancestry-aware modeling that accounts for differences in allele frequencies and linkage disequilibrium, and explicit per-ancestry calibration and validation. In practice, this equal performance is more likely when these steps are taken. Without diverse representation and proper calibration, accuracy often varies by ancestry because genetic architecture and variant frequencies differ between groups. So, the statement is best understood as true in well-validated, multi-ancestry contexts, but not guaranteed in all real-world applications. Always look for ancestry-specific performance metrics and calibration when evaluating a risk score.

10. Copy number variants in germline testing refer to which type of genetic change?

A. Single base substitutions.

B. Epigenetic changes.

C. Deletions or duplications that can be detected by methods like MLPA or microarray.

D. Balanced translocations.

Copy number variants are deletions or duplications of DNA segments that change the number of copies of a genomic region. In germline testing, these structural changes alter gene dosage rather than just the sequence, and they're detected by methods that measure copy number across the genome or targeted genes, such as MLPA or microarray. This distinguishes them from single base substitutions, which are small sequence changes, and from epigenetic changes, which modify gene expression without changing the DNA sequence, or from balanced translocations, which rearrange material between chromosomes without changing the overall copy number. CNVs are important in hereditary cancer because they can underlie pathogenic variants that sequencing alone might miss.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://heredirtarycancerrisktreatmentstrat.examzify.com

We wish you the very best on your exam journey. You've got this!